Abstract:We propose tests based on non-linear mixed effects models (NLMEM) in pharmacokinetic interaction and bioequivalence cross-over trials comparing two treatments or two formulations. To compare the logarithm of the area under the curve (AUC) using these models, two approaches are studied: in the first one, concentration data are analysed globally, with and without the estimation of a treatment effect; and in the second one, they are analysed separately in each treatment group with the estimation of the individual parameters. Four tests for comparison of the logarithm AUC between two treatment arms are studied: a likelihood-ratio test (LRT), a Wald test and two tests, parametric and non-parametric, comparing the individual Empirical Bayes (EB) estimates. These tests are adapted to the case of equivalence, except the LRT which does not have any simple extension. We evaluate by simulation of the type I error and the power for both comparison and equivalence tests. They are compared to the standard tests recommended by the FDA and the EMEA, based on non-compartmental (NC) AUC. Trials for a usual PK model are simulated under H(0) and several H(1) using S-plus software and analysed with the nlme function. Different configurations of the number of subjects (n=12, 24 and 40) and of the number of samples per subject (J=10, 5 and 3) are studied. The type I error alpha of LRT and Wald comparison test in the 5000 replications of interaction cross-over trials is found to be 20.9 per cent and 21.7 per cent, respectively, in the original design (n=12, J=10), which is far superior to 5 per cent, and decreases when n increases. When n is fixed, alpha is found to increase with J. Power is satisfactory for both tests, after correction of the significance threshold. Results of EB and NC tests are similar with satisfactory powers and a type I error close to 5 per cent, except when J=3 for EB tests. Similar results are obtained for equivalence tests, except for EB and NC Student tests, which are not of a great interest. NC tests keep their place when the number of samples per subject J is large, but NLMEM seem useful for cross-over studies performed in special populations where J limited; the evaluation by Monte-Carlo simulations of empirical threshold seems however necessary because of the inflation of the type I error.

Checking distributional assumptions for pharmacokinetic summary statistics based on simulations with compartmental models

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Efficient model-based bioequivalence testing

Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials

Exploring various measures of the area under the curve for the assessment of dose-proportionality and estimation of bioavailability

Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?

A Simulation Study of the Comparative Performance of Partial Area under the Curve (pAUC) and Partial Area under the Effect Curve (pAUEC) Metrics in Crossover Versus Replicated Crossover Bioequivalence Studies for Concerta and Ritalin LA

Statistical Analysis of Two-Compartment Pharmacokinetic Models with Drug Non-adherence

Comparative review of novel model-assisted designs for phase I clinical trials.

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

On modelling of bioavailability of drugs in terms of conservation laws

A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases

Statistical Analysis of One-Compartment Pharmacokinetic Models with Drug Adherence

Systematic Evaluation of Dose Proportionality Studies in Clinical Pharmacokinetics.

Physiological basis of multicompartmental models of drug distribution

Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

Bayesian Estimates of the Population-Pharmacokinetic Parameters with Symmetrical Error

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs